BridgeBio Pharma Reports Third Quarter Revenue Growth and EPS Beat
BridgeBio Pharma (BBIO) reported third-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted revenue of $353.17 million, representing a significant 192.6% increase year-over-year and beating estimates by $57.42 million. Despite the strong revenue performance, GAAP earnings per share (EPS) stood at -$0.42, which outperformed consensus estimates by $0.17. Following the announcement, shares saw a slight decline of 1.17% in after-hours trading as investors processed the results alongside upcoming clinical data and regulatory milestones.
Tickers: $BBIO